Business Standard

Serum Institute seeks Covovax EUA for 7- to 11-year age group

Pune-based vaxmaker conducting trials on children aged 2 yrs and above

vaccine
Premium

Sohini Das Mumbai
Pune-based Serum Institute of India (SII) has sought emergency-use authorisation (EUA) for its Covovax vaccine from the drug regulator for children aged between seven and 11 years, said sources in the know. If the approval comes through, this will be a global first for the vaccine for such an age group.

“SII has submitted the interim data from the clinical trials and sought EUA for the Novavax vaccine it manufactures in India under the name Covovax,” said a source close to the development.

SII withheld comment till the time of going to press. Earlier this month, SII had received the Drugs Controller

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Mar 24 2022 | 12:40 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com